Concurrent Chemoradiotherapy Combined With Immunotherapy in Patients With Potentially Resectable Pancreatic Cancer
Condition(s):Pancreatic CarcinomaLast Updated:December 5, 2022Recruiting
Hide Studies Not Open or Pending
Condition(s):Pancreatic CarcinomaLast Updated:December 5, 2022Recruiting
Condition(s):Pancreatic AdenocarcinomaLast Updated:October 18, 2022Completed
Condition(s):Pancreatic Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Endocrine Gland Neoplasms; Pancreatic Diseases; Digestive System Diseases; Endocrine System Diseases; Gemcitabine; Antimetabolites, AntineoplasticLast Updated:June 28, 2023Completed
Condition(s):Pancreatic AdenocarcinomaLast Updated:July 16, 2019Terminated
Condition(s):Pancreatic Cancer Metastatic; Pancreatic Adenocarcinoma MetastaticLast Updated:October 11, 2023Not yet recruiting
Condition(s):Pancreatic Cancer; Nab-paclitaxel; Gemcitabine; S1Last Updated:July 8, 2019Unknown status
Condition(s):Pancreatic Adenocarcinoma; Unresectable Pancreatic Carcinoma; Stage III Pancreatic Cancer AJCC v6 and v7; Stage IV Pancreatic Cancer AJCC v6 and v7Last Updated:March 19, 2024Active, not recruiting
Condition(s):Advanced Pancreatic CancerLast Updated:May 16, 2014Unknown status
Condition(s):Metastatic Pancreatic CancerLast Updated:November 10, 2015Unknown status
Condition(s):Pancreatic CancerLast Updated:March 18, 2024Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.